An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

• Status: Completed
• Trial end date: 2012-11-16
• Target enrollment: 0
• Participant gender: Female

Summary

This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without progression for at least three years. Patients will be followed prospectively for one year.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Trastuzumab

Criteria

Inclusion Criteria:

• Female patients, >/= 18 years of age

• HER2-positive metastatic breast cancer or locally advanced breast cancer

• Systemic treatment included Herceptin as 1st line therapy

• Without progression for at least 3 years after the beginning of Herceptin treatment

• Alive or not alive and treated or not treated with Herceptin at the time of inclusion

Exclusion Criteria:

• Disease progression <3 years after beginning 1st-line therapy with Herceptin